Cytomegalovirus infections

Dermatologic Clinics

Volumn 20, Issue 2, 2002, Pages 291-299

  Khoshnevis, Mohamad ^a   Tyring, Stephen K ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; CIDOFOVIR; FOMIVIRSEN; FOSCARNET; GANCICLOVIR; ZIDOVUDINE;

BONE MARROW TOXICITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOMEGALOVIRUS; HIGH RISK PATIENT; HUMAN; IN SITU HYBRIDIZATION; IRITIS; NEPHROTOXICITY; NEUTROPENIA; PANCYTOPENIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SKIN ULCER; UVEITIS; VIRION; VIRUS CULTURE; VIRUS INFECTION; CYTOMEGALIC INCLUSION BODY DISEASE; VIRAL SKIN DISEASE;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMAN; SKIN DISEASES, VIRAL; HUMANS;

EID: 0036082740     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(01)00007-9     Document Type: Review

References (93)

1. Mini review: Summary of the II International Symposium on Cytomeglovirus
2. Cytomegalovirus infection in normal and immunocompromised humans
3. Human cytomegalovirus latency and reactivation: A delicate balance between the virus and its host's immune system
4. Cytomegalovirus
5. Human cytomegalovirus infection of cultured fibroblasts, II: Viral replicative sequence of a wild and an adapted strain
6. Herpes simplex viruses and their replication
7. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains
8. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169
9. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus
10. Human cytomegalovirus glycoproteins
11. Identification of a 65000 dalton virion envelope of human cytomegalovirus
12. Regulation of human cytomegalovirus gene expression
13. Hyperimmediate entry of human cytomegalovirus virions and dense bodies into human fibroblasts
14. Role of reactive oxygen intermediates in cytomegalovirus gene expression and in the response of human smooth muscle cells to viral infection
15. Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus
16. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1
17. Human cytomegalovirus infection inhibits G1/S transition
18. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb and p53, leading to cell cycle arrest
19. Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G-1 to S
20. Cytomegalovirus and their replication
21. The pathogenecity of cytomegalovirus
22. Human cytomegalovirus cell tropism and pathogenesis
23. Cytomegalovirus and latency: An overview
24. Localization of Human Cytomegalovirus in peripheral blood leukocytes by in situ hybridization
25. Interaction of cytomegalovirus with leucocytes from patients with mononucleosis due to cytomegalovirus
26. Disseminated cytomegalovirus infection: Molecular analysis of virus and leucocyte interactions in viremia
27. Interactions of human cytomegalovirus with leukocytes in vivo: Analysis by in situ hybridization
28. Cytomegalovirus infection in human blood cells
29. Cytomegalovirus infects human lymphocytes and monocytes: Virus expression is restricted to immediate-early gene products
30. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells
31. Human cytomegalovirus productivity infects primary differentiated macrophages
32. Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages
33. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers
34. Phorbol esterinduced differentiation permits productive human cytomegalovirus infection in a monocytic cell line
35. A novel mechanism for persistence of human cytomegalovirus in macrophages
36. Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: An in vitro model
37. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with an active CMV infection
38. Circulating endothelial giant cells permissive for human cytomegalovirus (HCMV) are detected in disseminated HCMV infections with organ involvement
39. TORCH syndrome
40. Manifestations cutanees des infections a cytomegalovirus
41. Cytomegalovirus
42. Posttransfusion cytomegalovirus infections
43. Treatment of cytomegalovirus
44. Cytomegalovirus infection in the normal host
45. Vasculitis in cytomegalovirus infection
46. Fatal disseminated cytomegalovirus infection in an apparently normal adult
47. Cytomegalovirus disease of the gastrointestinal tract in patients without AIDS
48. Summary of the international consensus symposium on management of HIV, CMV, and hepatitis virus infections
49. Cytomegalovirus infection involving the skin in immunocompromised hosts, a clinicopathologic study
50. Histologically specific skin lesions in disseminated cytomegalovirus infection
51. Cytomegalovirus infection
52. Cytomegalovirus inclusion disease of the skin
53. Unusual cutaneous cytomegalovirus involvement in patients with acquired immunodeficiency syndrome
54. Clinically occult cytomegalovirus present in skin biopsy specimens in immunosuppressed hosts
55. Vesiculobullous lesions caused by cytomegalovirus infection in an immunocompromised adult
56. A blistering rash and swollen knees
57. Papular-purpuric gloves-and-socks syndrome related to cytomegalovirus infection
58. Systemic lupus erythematosus and concurrent cytomegalovirus vasculitis: Diagnosis by antemortem skin biopsy
59. Diagnosis and treatment of a case of cutaneous cytomegalovirus infection with a dramatic clinical presentation
60. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo
61. Quantitation of cytomegalovirus: Methodologic aspects and clinical applications
62. Early treatment with gancyclovir to prevent cytomegalovirus disease after allogenic bone marrow transplant
63. Preemptive therapy in immunocompromised hosts
64. A randomized controlled trial of prophylactic gancyclovir for cytomegalovirus pulmonary infection in recipients of allogenic bone marrow transplants
65. Plasma PCR for cytomegalovirus DNA after allogenic marrow transplantation: Comparison with PCR using peripheral blood leucocytes, pp65 antigenemia and viral culture
66. Cytomegalovirus (CMV) viremia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease
67. Comparative quantitation of human cytomegalovirus DNA in blood leucocytes and plasma of transplant and AIDS patients
68. Direct detection of cytomegalovirus in peripheral blood leukocytes: A review of the antigenemia assay and polymerase chain reaction
69. Surveillance of blood, urine, and throat specimens are not valuable for predicting cytomegalovirus disease in liver transplant recipients
70. Cytomegalovirus (CMV) viremia and CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus
71. Risk for retinitis in patients with AIDS can be assessed by quantitation of threshold levels of cytomegalovirus DNA burden in blood
72. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection
73. Oral infections due to cytomegalovirus in immunocompromised patients
74. Viral dynamics during active CMV infection and pathology
75. Human cytomegalovirus infection of the major leukocyte subpopulations and evidence for initial viral replication in polymorphonuclear leukocytes from viremic patients
76. The lower matrix pp65 is the principal viral antigen present in peripheral blood leukocytes during an active cytomegalovirus infection
77. Nuclear expression of the lower matrix protein of the human cytomegalovirus in peripheral blood leukocytes of immunocompromised viraemic patients
78. Cytomegalovirus antigenemia as a useful marker of a symptomatic cytomegalovirus infection after renal transplantation: A report of 130 consecutive patients
79. The role of Epstein-Barr virus in lymphoepithelioma-like caricinomas
80. Comparison of plasma PCR and bronchoalveolar lavage fluid culture for detection of cytomegalovirus infection in adult bone marrow transplant recipients
81. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections
82. Comparison of nested PCR for detection of DNA in plasma with pp65 leukocytic antigenemia procedure for diagnosis of human cytomegalovirus infection
83. Cytomegalovirus pp65 antigenemia-guided early treatment with gancyclovir versus gancyclovir at engraftment after allogenic marrow transplant: A randomized, double-blinded study
84. Cytomegalovirus infection in patients with AIDS
85. Syntex collaborative treatment study group: Gancyclovir treatment of life- or sight-threatening cytomegalovirus infection experience in 314 immunocompromised patients
86. Gancyclovir absolute bioavailability and steady-state pharmacokinetics after oral administration of two 3000-mg/d dosing regimens in human immunodeficiency virus- and cytomegalovirus-seropositive patients
87. Oral Ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS
88. Treatment of cytomegalovirus retinitis with zidovudine and gancyclovir in patients with AIDS: Outcome and toxicity
89. Foscarnet: A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections
90. Cytomegalovirus infection in patients with HIV infection
91. Toxic epidermal necrolysis occurring as a consequence of treatment with foscarnet
92. Cidofovir for cytomegalovirus infection and disease in allogenic stem cell transplant recipients